(This Feb 6. story has been corrected to show the damages are according to an expert report, and not estimated by IHH's unit. The error also appeared in an earlier version of the story.) (Reuters) - I ...
Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...
Daiichi Sankyo Co. said on Friday it submitted its mRNA-based COVID-19 vaccine for regulatory approval in Japan. Approval would give Japan a home-grown mRNA vaccine of the type that have made up ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...
Thank you very much for waiting. We will now would like to start Daiichi Sankyo's Financial Results Briefing for the Third Quarter of Fiscal Year 2024. My name is Asakura from Corporate ...
This partnership highlights both companies’ commitment to improving healthcare by equipping cardiologists with cutting-edge knowledge and skills in interventional cardiology. The MoU is part of a ...
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39 ...
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives Daiichi Sankyo’s Turalio some company in a rare tumor type.
In a report released yesterday, Seiji Wakao from J.P. Morgan maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report), with a price target of Yen6,000.00. The company’s ...